Herantis Pharma is focused on developing innovative therapies aimed at modifying the progression of neurodegenerative diseases, particularly Parkinson's disease. Their lead product, HER-096, is designed to address the underlying pathology of Parkinson's by targeting the degeneration of dopamine neurons in the brain. Unlike current treatments that only alleviate symptoms by increasing dopamine levels, HER-096 aims to slow, stop, or even reverse neuronal degeneration, potentially offering patients a significant improvement in their quality of life and a reduction in severe symptoms associated with the disease.

The company is currently conducting clinical trials to evaluate the safety, tolerability, and pharmacokinetic properties of HER-096. A Phase 1b trial is underway, involving both healthy volunteers and patients with Parkinson's disease, to assess the effects of repeated subcutaneous doses of the therapy. Preliminary results from a Phase 1a trial have shown a favorable safety profile and pharmacokinetic characteristics that align with preclinical data, indicating that HER-096 reaches pharmacologically active concentrations in the cerebrospinal fluid. This research is crucial for establishing HER-096 as a viable disease-modifying treatment for Parkinson's disease, with the potential to significantly impact patient outcomes.

Finland

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. A Phase 1a clinical trial has demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Herantis Pharma

Company Details